...
首页> 外文期刊>Research in Microbiology >High precision microfluidic microencapsulation of bacteriophages for enteric delivery
【24h】

High precision microfluidic microencapsulation of bacteriophages for enteric delivery

机译:高精度微流体微胶囊抑制肠送货

获取原文
获取原文并翻译 | 示例

摘要

ASalmonellaspecific bacteriophage Felix O1 (Myoviridae) was microencapsulated in a pH responsive polymer formulation. The formulation incorporated a pH responsive methacrylic acid copolymer Eudragit? S100 (10% (w/v)) with the addition of the biopolymer sodium alginate, the composition of which was varied in the range (0.5% (w/v)–2% (w/v)). The microencapsulation process employed commercially available microfluidic droplet generation devices. We have used readily available low cost microfluidic chips instead of bespoke in-house fabricated glass capillary devices which are accessible only in specialist research facilities. We show that these co-flow microfluidic devices can easily be used to prepare phage encapsulated microparticles making them suitable for use by both the phage research community and industry in order to evaluate and optimise phage compatible formulations for microencapsulation. A novelty of the work reported here is that the size of the generated monodispersed droplets could be precisely controlled in the range 50?μm–200?μm by varying the flow rates of the dispersed and continuous phases. Consequently, alginate concentration and microparticle size were shown to influence the phage release profile and the degree of acid protection afforded to phages upon exposure to simulated gastric fluid (SGF). Bigger microparticles (~100?μm) showed better acid protection compared with smaller beads (~50?μm) made from the same formulation. Increasing the alginate composition resulted in improved acid protection of phages for similar particle sizes. The high viscosity formulations containing higher amounts of alginate (e.g. 2% (w/v)) negatively affected ease of droplet generation in the microfluidic device thereby posing a limitation in terms of process scale-up. Felix O1 encapsulated in the formulation containing 10% (w/v) ES100 and 1% (w/v) alginate showed excellent protection upon exposure of the gelled microparticles to SGF (pH 1 for 2?h) without the use of any antacids in the encapsulation matrix. Encapsulated phages previously exposed to SGF (pH 1 for 2?h) were released at elevated pH in simulated intestinal fluid (SIF) and were shown to arrest bacterial growth in the log growth phase. We have therefore demonstrated the microencapsulation of phages using readily available microfluidic chips to produce solid dosage microcapsule forms with a rapid pH triggered release profile suitable for targeted delivery and controlled release in the gastrointestinal tract.
机译:AsalmonellaSpecific噬菌体肝细胞素e1(myoviridae)在pH响应聚合物制剂中微胶囊化。该制剂掺入pH响应甲基丙烯酸共聚物EUDRAGIT? S100(10%(w / v))加入生物聚合物藻酸钠,其组合物在范围内变化(0.5%(w / v)-2%(w / v))。微胶囊化工艺采用市售的微流体液滴产生装置。我们使用的是可用的低成本的微流体芯片而不是定制的内部制造的玻璃毛细管装置,只能在专业的研究设施中获得。我们表明,这些共流式微流体装置可以容易地用于制备噬菌体封装的微粒,使其适用于噬菌体研究群落和工业的使用,以便评估和优化微胶囊的噬菌体兼容配方。这里报道的工作新颖的是通过改变分散和连续相的流速来精确地控制所产生的单分散液滴的尺寸。因此,示出了海藻酸盐浓度和微粒尺寸以影响噬菌体释放曲线和在暴露于模拟胃液(SGF)时对噬菌体提供的酸保护程度。与相同配方制成的较小珠子(〜50μm)相比,微颗粒(〜100μm)显示出更好的酸保护。增加藻酸盐组合物导致含有类似颗粒尺寸的湿法的酸保护。含有较高量的藻酸盐的高粘度制剂(例如2%(w / v))对微流体装置中的液滴产生负面影响,从而在过程展示方面造成限制。在含有10%(w / v)ES100和1%(w / v)藻酸盐的制剂中封装在含有10%(w / v)的制剂中,在不使用任何抗酸剂的情况下在凝胶化的微粒至SGF(pH 1持续2μl)时显示出优异的保护。封装矩阵。在模拟肠液(SIF)的升高的pH下,在pH升高的pH下释放先前暴露于SGF(pH1的pH1)的包封噬菌体,并显示在日志生长阶段中的细菌生长。因此,我们已经证明了使用易于使用的微流体芯片的噬菌体的微胶囊,以产生固体剂量微胶囊,其具有快速pH触发释放曲线,适用于胃肠道中的靶向递送和控制释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号